Looking Closely at the Growth Curve for Adverum Biotechnologies Inc. (ADVM) – News Heater
Home  »  Business   »  Looking Closely at the Growth Curve for Adverum Bi...

Looking Closely at the Growth Curve for Adverum Biotechnologies Inc. (ADVM)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Adverum Biotechnologies Inc. (NASDAQ:ADVM) went up by 0.50% from its latest closing price compared to the recent 1-year high of $14.79. The company’s stock price has collected -4.69% of loss in the last five trading sessions. Press Release reported on 11/04/21 that Adverum Reports Third Quarter 2021 Results

Is It Worth Investing in Adverum Biotechnologies Inc. (NASDAQ :ADVM) Right Now?

Plus, the 36-month beta value for ADVM is at 1.09. Opinions of the stock are interesting as 1 analysts out of 3 who provided ratings for Adverum Biotechnologies Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $5.00, which is $2.22 above the current price. ADVM currently public float of 96.08M and currently shorts hold a 9.02% ratio of that float. Today, the average trading volume of ADVM was 2.04M shares.

ADVM’s Market Performance

ADVM stocks went down by -4.69% for the week, with a monthly jump of 4.64% and a quarterly performance of -11.74%, while its annual performance rate touched -85.71%. The volatility ratio for the week stands at 5.05% while the volatility levels for the past 30 days are set at 5.24% for Adverum Biotechnologies Inc.. The simple moving average for the period of the last 20 days is -6.39% for ADVM stocks with a simple moving average of -58.86% for the last 200 days.

Analysts’ Opinion of ADVM

SVB Leerink, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $5. The rating they have provided for ADVM stocks is “Mkt Perform” according to the report published on May 03rd, 2021.

Truist gave a rating of “Hold” to ADVM, setting the target price at $9 in the report published on April 29th of the current year.

ADVM Trading at -5.77% from the 50-Day Moving Average

After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.27% of loss for the given period.

Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 5.05%, as shares surge +6.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.45% lower at present.

During the last 5 trading sessions, ADVM fell by -4.69%, which changed the moving average for the period of 200-days by -85.26% in comparison to the 20-day moving average, which settled at $2.17. In addition, Adverum Biotechnologies Inc. saw -81.27% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADVM starting from Scopa James Paul, who sale 50,000 shares at the price of $2.18 back on Nov 15. After this action, Scopa James Paul now owns 3,334 shares of Adverum Biotechnologies Inc., valued at $109,000 using the latest closing price.

Clark Julie, the Chief Medical Officer of Adverum Biotechnologies Inc., sale 4,766 shares at $2.17 during a trade that took place back on Sep 30, which means that Clark Julie is holding 164,723 shares at $10,342 based on the most recent closing price.

Stock Fundamentals for ADVM

The total capital return value is set at -35.08, while invested capital returns managed to touch -35.40. Equity return is now at value -37.80, with -30.30 for asset returns.

Based on Adverum Biotechnologies Inc. (ADVM), the company’s capital structure generated 7.08 points at debt to equity in total, while total debt to capital is 6.61. Total debt to assets is 6.37, with long-term debt to equity ratio resting at 6.05. Finally, the long-term debt to capital ratio is 5.65.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of -31.48, with the company’s debt to enterprise value settled at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.82.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam